Structure-Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
12
06
2024
revised:
15
07
2024
accepted:
24
07
2024
pmc-release:
12
09
2025
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
18
9
2024
Statut:
epublish
Résumé
Despite the availability of medicines preventing respiratory syncytial virus (RSV) infection, post-exposure treatment options are needed for addressing patient's needs. RSV non-nucleoside polymerase inhibitors (NNI) have emerged as a promising asset for which our group previously disclosed JNJ-8003 with potent
Identifiants
pubmed: 39291020
doi: 10.1021/acsmedchemlett.4c00272
pmc: PMC11403738
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1549-1558Informations de copyright
© 2024 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare the following competing financial interest(s): All authors are or were previously employed by Johnson and Johnson Innovative Medicine and are possible shareholders.